scholarly journals Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer

2015 ◽  
Vol 17 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Y Sunakawa ◽  
S Cao ◽  
M D Berger ◽  
S Matsusaka ◽  
D Yang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Estrogen Receptor ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Estrogen Receptor Beta ◽  
Genetic Variations ◽  
Locally Advanced Gastric Cancer ◽  
Receptor Beta

A prospective randomized trial comparing 5-fluorouracil (5-FU), mitomycin-C (MMC), and polysaccharide-K (PSK) versus UFT and PSK as adjuvant chemoimmunotherapy (CITX) for patients with locally advanced gastric cancer with curative resection

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15074-15074
Author(s):  
J. Choi ◽  
S. Kang ◽  
J. Park ◽  
H. Lee ◽  
Y. Cho ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Randomized Trial ◽  
Advanced Gastric Cancer ◽  
Curative Resection ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Target Number ◽  
Stage Ib ◽  
Locally Advanced Gastric Cancer

15074 Background: Adjuvant chemotherapy has demonstrated small but significant survival benefit in locally advanced gastric cancer in several meta-analyses, while adjuvant CITX showed improved outcome of patients (pts) compared to chemotherapy alone in a few trials. However, optimal chemotherapy regimen remains to be determined. We conducted a randomized trial comparing oral (PO) CITX with intravenous (IV) CITX in gastric cancer pts with curative resection. Methods: All enrolled pts underwent radical surgery with at least D2 dissection. After stratification for pathologic stage (IB or II vs. III) and primary tumor size (=5 cm vs. >5 cm), pts were randomized to IV CITX (5-FU 500 mg/m2 weekly for 24 weeks, MMC 8 mg/m2 every 6 weeks x 4) or PO CITX (UFT 400–600 mg/day for 12 months). Pts in both arms received PSK 3 g/day PO for 4 months. The planned target number of pts was 368 to prove the non-inferiority of PO CITX compared to IV CITX in overall survival. Results: A total of 82 pts (stage IB: 6, II: 29, IIIA: 30, IIIB: 17; 44 in IV arm, 38 in PO arm) were enrolled between May 2002 and October 2005, when the trial was closed due to poor accrual. Pts characteristics were well balanced. With a median follow-up of 39 months (14–55 months) in survivors, there were no significant differences in 3-year disease-free survival (82% vs. 61%, p=0.302) and overall survival (84% vs. 79%, p=0.838) between IV and PO arms. No grade 4 toxicity was observed in both arms. IV arm demonstrated higher incidence of grade 2 or 3 neutropenia (79% vs. 52%, p=0.025), thrombocytopenia (19% vs. 0%, p=0.008), and vomiting (36% vs. 9%, p=0.013). Conclusions: Although accrual was well below that planned, the results of this trial suggest that PO CITX with UFT might have similar efficacy with lower toxicity profile compared with 5-FU and MMC CITX in adjuvant treatment for gastric cancer. No significant financial relationships to disclose.

Significance of Prognostic Nutritional Index in post-surgical outcomes after surgical management in gastric cancer patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15535-e15535
Author(s):  
Marytere Herrera ◽  
Nora Sobrevilla-Moreno ◽  
IVAN LYRA-GONZALEZ ◽  
German Calderillo ◽  
Consuelo Diaz ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Nutritional Status ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Prognostic Nutritional Index ◽  
Locally Advanced Gastric Cancer ◽  
Nutritional Index ◽  
Gastric Cancer Patients

e15535 Background: Preoperative nutritional status in gastric cancer patients is not only correlated with postoperative complications, also, prognostic nutritional index or Onodera´s nutritional index (PNI) may relate with overall survival (OS) after gastrectomy. There is no available data of preoperative nutritional status in Mexican population. We decide to explore these variables and analyze its impact in outcomes reported in our population. Methods: This is a retrospective included a total of 91 patients patients with locally advanced gastric cancer confirmed by laparoscopy treated in the National Cancer Institute in México between January 2010 and June 2016. The PNI level was determined according the following formula: 10 x serum albumin (g/dl) + 0.005 x total lymphocyte count (per mm3). The optimal cutoff value of PNI in our population was set at 38.7 according the median, we stratified patients in high (PNI > 38.7) or low (PNI < 38.7) nutritional status, clinicopathologic features were compared. Results: We analyzed 91 patients, the mean patients age was 58, 61.5% were man, the 51.6% went to total gastrectomy with D2 dissection, 56% were pathologic stage III and 61.5% of the patients received adjuvant chemotherapy. The patients with high nutritional status had a OS of 46 months vs patients with low nutritional status with 25 months (p = 0.009). Patients with body mass index (BMI) > 23 had a OS of 41 months vs patients with BMI < 23 with 19 months of OS (p = 0.001), finally the patients with albumin > 3.75 had a 39 months of OS vs 23 months with albumin < 3.75 (p = 0.011) Conclusions: The low PNI group had worse OS than the high PNI group (46 months vs 25 months, p = 0.009). Preoperative is a simple and useful marker to predict overall survival in patients with locally advanced gastric cancer

Influence of perineural invasion in predicting overall survival and disease-free survival in patients With locally advanced gastric cancer

2017 ◽  
Vol 213 (4) ◽  
pp. 748-753 ◽  
Author(s):  
Paolo Aurello ◽  
Giammauro Berardi ◽  
Simone Maria Tierno ◽  
Gian Luca Rampioni Vinciguerra ◽  
Fabio Socciarelli ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Perineural Invasion ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Free Survival ◽  
Locally Advanced Gastric Cancer ◽  
Disease Free

CPT-11/Cisplatin neoadjuvant therapy downstages locally advanced gastric cancer

2001 ◽  
Vol 120 (5) ◽  
pp. A129-A129
Author(s):  
E NEWMAN ◽  
S MARCUS ◽  
M POTMESIL ◽  
H HOCHSTER ◽  
H YEE ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Neoadjuvant Therapy ◽  
Advanced Gastric Cancer ◽  
Locally Advanced ◽  
Locally Advanced Gastric Cancer
Sign in / Sign up

Export Citation Format

Share Document